← Back to Clinical Trials
Recruiting NCT06692569

NCT06692569 The Effect of Modified Constraint Induced Movement Therapy on Upper Extremity Function in Stroke Rehabilitation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06692569
Status Recruiting
Phase
Sponsor University of Jazan
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 34 participants
Start Date 2024-11-12
Primary Completion 2025-07-13

Eligibility & Interventions

Sex All sexes
Min Age 45 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Conventional Physical TherapyModified Constraint Induced Movement Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 34 participants in total. It began in 2024-11-12 with a primary completion date of 2025-07-13.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of the study is to determine the effect of Modified Constraint-Induced Movement Therapy and trunk restraint contrasted with conventional physical therapy treatment on improving upper extremity function, balance, and quality of life among chronic hemiplegic patients. * To find out the effectiveness of conventional physical therapy treatment on improving upper extremity function, balance, and quality of life among chronic hemiplegic patients. * To find out the effectiveness of modified constraint induced movement therapy (mCIMT) and trunk restraint along with conventional physical therapy treatment on improving upper extremity function, balance, and quality of life among chronic hemiplegic patients. * To find out the effectiveness of modified constraint induced movement therapy (mCIMT) and trunk restraint combined with conventional physical therapy treatment versus conventional physical therapy treatment alone on improving upper extremity function, balance, and quality of life among chronic hemiplegic patients.

Eligibility Criteria

Inclusion Criteria: * Right or left-sided chronic hemiplegic patients. * Onset of stroke More than six months. * Age between 45 to 65 years of both genders. * Mini-Mental State Examination - Scored more than 24/30. * Modified Ashworth Scale for spasticity 1 or 1+. * Have at least 20° wrist active extension and at least 10° of metacarpophalangeal active extension of the paretic upper extremity. * Have at least grade 2/5 of muscle power on upper extremity especially in wrist extensors. * Have normal visual perception. * With no other neurological disorders. Exclusion Criteria: * Unable to follow visual and oral commands. * Unilateral neglect. * Severe cognitive, or language deficits.

Contact & Investigator

Central Contact

Mohammed Mansour Al Shehri, PhD

✉ moalshehri@jazanu.edu.sa

📞 00966-503946253

Principal Investigator

Karthick BALASUBRAMANIAN, MPT

PRINCIPAL INVESTIGATOR

University of Jazan

Frequently Asked Questions

Who can join the NCT06692569 clinical trial?

This trial is open to participants of all sexes, aged 45 Years or older, up to 65 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06692569 currently recruiting?

Yes, NCT06692569 is actively recruiting participants. Contact the research team at moalshehri@jazanu.edu.sa for enrollment information.

Where is the NCT06692569 trial being conducted?

This trial is being conducted at Riyadh, Saudi Arabia.

Who is sponsoring the NCT06692569 clinical trial?

NCT06692569 is sponsored by University of Jazan. The principal investigator is Karthick BALASUBRAMANIAN, MPT at University of Jazan. The trial plans to enroll 34 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology